Trial · NCT05535322
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Major acute cardiovascular events | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | In this work, this composite includes patients suffering from non-fatal acute myocardial infarction (AMI) and non-fatal stroke, transient ischemic attack (TIA), all-cause death, and, heart failure events occurring during the study period (from inclusion in the study until the event or the end of the study period, whichever came first). |
| Secondary | Major acute cardiovascular events without heart failure | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | In this work, this composite includes patients suffering from non-fatal acute myocardial infarction (AMI) and non-fatal stroke, transient ischemic attack (TIA) and all-cause death occurring during the study period (from inclusion in the study until the event or the end of the study period, whichever came first). |
| Secondary | AMI | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | Acute myocardial infarction events occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first. |
| Secondary | Stroke | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | Stroke events occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first. |
| Secondary | Heart Failure | Through study completion (from inclusion in the study until the event or the end of the study period, whichever came first) | Heart failure hospitalization occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first. |
| Secondary | all-cause death | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | Death from all causes occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first. |
| Secondary | Renal progression | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | Sustained 40% reduction in eGFR occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first. |
| Secondary | atrial fibrillation | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | Events of atrial fibrillation episodes occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first. |
| Secondary | Hypoglycemia | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | Severe hypoglycemia requiring hospitalization occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first. |
| Secondary | Persistence | From inclusion in the study, starting from 01/01/2014, until the end of the study, on 31/12/2019. | Persistence on treatment was defined as the percentage of patients continuing treatment from the start of the study period or since the first prescription during the study period until evidence of discontinuation or the end of the study period. |
| Secondary | Adherence | From inclusion in the study, starting from 01/01/2014, until the end of the study, on 31/12/2019. | Treatment adherence was defined as the proportion of days covered (days in which an individual had access to the medication) from the start of the study period or since the first prescription during the study period until treatment discontinuation |
| Secondary | Therapeutic inertia | From inclusion in the study, starting from 01/01/2014, until the end of the study, on 31/12/2019. | Therapeutic inertia was defined as non-intensification of treatment once started despite HbA1c ≥7.5% during follow-up. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05535322/registered